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MELATONIN USE IN SLEEP DISORDERS
Clinically significant sleep disorders affect at least 10% of Western populations, and one third or more of the population suffers daily from a sleep disturbance or excessive daytime sleepiness. [1] Management of many of these sleep disorders often requires complex therapeutic regimens, involving both pharmacological and non-pharmacological interventions.
When considering pharmacological management of sleep disorders, drugs which have a short half-life are preferable to minimise 'hangover' effects the following morning. It is strongly recommended long term drug therapy should also be avoided, as dependence and tolerance can develop. [2, 3] Previous studies have highlighted the potential use of melatonin in treating primary and secondary [4] sleep disorders in adults [5, 6, 7] and others have indicated melatonin can decrease sleep onset latency and increase the total time asleep, thus improving sleep quality overall. [8] Ferracioli-Oda et al [9] verified using melatonin in adults with primary sleep disorders improves sleep parameters (i.e., a higher dose has a greater effect on sleep latency and total sleep time).
Melatonin was first described in 1958 by dermatologist, Aaron Lerner, [10] as a hormone produced by the pineal gland from the essential amino acid tryptophan (Nacetyl-5-methoxytryptamine). Exogenous melatonin has no reported tolerance, dependence, or 'hangover effect' [11] , and no adverse effect on alertness or mood the following day [12] , as well as minimal side-effects (e.g., headache, dizziness, nausea, drowsiness) [13, 14] if administered at a low dose. [15] Melatonin has a short half-life of only 30-50 minutes and can induce phase shifts in the circadian timing system (both central and peripheral clocks) and when administered acutely, reduces core body temperature and lowers alertness, encouraging sleep propensity. [16] M A N U S C R I P T
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BIOLOGY OF MELATONIN
In humans, the primary physiological function of melatonin is to reinforce darknessrelated behaviour, such as sleep propensity. [16] Inadequate sleep can not only lead to a reduction in daytime performance and excessive sleepiness, but chronic inadequate sleep may lead to immunosuppression and increased cancer-stimulatory cytokine production. [17] Endogenous melatonin synthesis is finely regulated by visual light cues received by the hypothalamic suprachiasmatic nucleus in the brain, the site of the major circadian oscillator. During daylight hours, perceived light signals inhibit melatonin production. Conversely, at night when no light signals are received, melatonin synthesis and release occur with levels peaking in the early hours of the morning.
Melatonin is metabolised by the liver, which processes >90% of the circulating hormone and together with its metabolites, is excreted in the urine. There is vast inter-individual variability in the quantity of melatonin produced depending on pineal gland size. Despite this, each person will have a similar bell-shaped production curve, which is reproducible from day to day. [16] Melatonin production declines as we age [18] due to several factors. The lower peak levels of endogenous serum melatonin [19] may be due to decreased pineal melatonin synthesis at night [20] , or gradual pineal gland calcification [21] . Endogenous melatonin synthesis may be further reduced by drugs (e.g. benzodiazepines, NSAIDs, and calcium channel blockers) which many elderly patients are likely to be prescribed. Beta-blockers, such as albuterol, have also been shown to oppose the sympathetic stimulation of melatonin synthesis. [22] In terms of the soporific effect of acutely administered melatonin, studies have In summary, exogenous melatonin administration can be used to mimic the physiological functions of endogenous low level melatonin when administered in a specifically timed manner (i.e., to correct abnormalities in circadian timing), or be used as a soporific/other agent when given in high doses for other types of sleep disorders since melatonin does not appear to suppress rapid eye movement (REM) sleep nor does it delay the onset of REM.
[27] Recent reviews in the medical literature have demonstrated exogenous melatonin is safe with short term use, but evidence of its effects on secondary sleep disorders is of low quality. [4] The aim of this systematic review was to summarise the current evidence-base for the role of exogenously administered melatonin in the treatment of primary sleep disorders. 
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Delayed Sleep Phase Syndrome (DSPS)
Schedule sleep earlier and decrease late night activity.
Phototherapy and strict sleep schedule. [29] Evening administration of melatonin (0.3-5mg) between 7pm and 8pm shifts circadian rhythms to an earlier time. [29, 30] 
Advanced Sleep Phase Syndrome (ASPS)
Combined phototherapy and bright light exposure in the evening. [31] Insufficient data to recommend use of melatonin for treatment of ASPS in adults. [31] 
Non-REM Parasomnia
Clonazepam, tricyclic antidepressants and benzodiazepines. [19] No trials conducted for the use of melatonin in parasomnias in adults. [19] Blind/non-24 h Sleep Wake Syndrome
Regulation of bed-times. [32] Evening administration of melatonin achieved phase advance in sighted individuals. [32] Timed melatonin also successfully entrained rhythms in blind individuals. [33, 34] Primary Insomnia 2. Non-benzodiazepine agonists and MT1/MT2 receptor agonists are safer for long term use than traditional benzodiazepines. [35] Melatonin agonist ramelteon approved in 2005. [35] M A N U S C R I P T A C C E P T E D Study Selection: All titles and abstracts were assessed and full texts of the relevant studies were obtained if they fulfilled the required inclusion criteria (see below).
Selected publications were assessed by two reviewers (FA & RR) separately to reduce selection bias using pre-defined criteria from the Jadad scale. [40] Although the Jadad scale for scoring does have its critics, it is a widely-used standard instrument for the assessment of papers to be included in a meta-analysis. Once a list of articles was created that each reviewer felt met the inclusion criteria they met to compare results and discuss which articles would be included in the final analysis.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
9
Study Type: The inclusion criteria were the trials had to be RCT, single or doubleblind, cross-over or parallel. All studies that did not meet the criteria or were not peer-reviewed, published trails were not included in the meta-analysis. There was no time limit on trial duration. The effect of melatonin was compared with placebo treatment in primary sleep disorders: primary insomnia, RBD, DSPS, or non-24 h sleep wake disorder. Qualitative, unpublished, duplicate studies, and those, which
were not easily translated, were excluded.
Study Group: Adults over the age of 18 years with an established primary sleep disorder.
Date of Publication:
Studies published between 1990 -2015 were eligible.
Sample Size: There were no restrictions on sample size.
Data Extraction and Analysis:
The author, year of publication, number of participants, type of study, details of melatonin regimen, and methods used were recorded for each of the chosen RCTs (Table 1 ). Data were assessed by two independent reviewers and relevant extracted data were tabulated ( Meta-analysis was performed using a continuous outcome measure across all the included evidence. The measure of effect size was the total mean difference, comparing the change from baseline for both melatonin and placebo in improving sleep onset latency. Alternative treatments, such as cognitive-behavioural therapy [42] were not included to keep the meta-analysis strictly between melatonin and placebo and remove any other non-medication variables, such as therapy. A fixed [43] Potential publication bias among studies was assessed by the use of funnel plots for each sleep disorder.
RESULTS
A total of 5030 articles were identified in the initial database and hand search (3696 EMBASE, 790 MEDLINE, 496 PsycINFO, 48 SCOPUS) of journals. From this, 361
abstracts were assessed and 28 met inclusion criteria. Fifteen articles were then excluded for reasons described below, resulting in a final 13 which were included ( (DSM-V) [59] were published, and therefore, the participants were selected based on those diagnostic criteria. If these studies were replicated now using the new diagnostic codes, findings might differ due to slightly different populations being tested. The ICSD-3 differs from the ICSD-2 in that the ICSD-2 "…described primary insomnia subtypes such as psychophysiological insomnia, idiopathic insomnia, inadequate sleep hygiene, and paradoxical insomnia, as discrete diagnostic entities." [58] Patients who meet the diagnostic criteria for only one subtype are very rare and the diagnostic criteria have been established for the subtypes of insomnia "…represent generic characteristics (e.g., engaging in sleep-disruptive habits;
underestimation of sleep time, evidence of conditioned arousal) of insomnia…and do not facilitate discrimination among these subtypes or between these subtypes and those presumed to have "secondary" forms of insomnia." [58] The ICSD-3 also
states, "…the current manual abandons the previously employed complex and highly specific insomnia classification scheme described by the original ICSD and the ICSD-2 in favour of a more global and defensible nosology." The ICSD-3 now includes three categories to diagnose insomnia: chronic insomnia disorder, shortterm insomnia disorder, and other insomnia disorder. [58] Primary insomnia is not due to a medical or psychiatric condition or medicine/substance abuse. It is particularly common in the elderly population and is often a long term problem; 69% of older people monitored for one year still suffer M A N U S C R I P T
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recommend melatonin replacement therapy may prove beneficial due to peak excretion of melatonin being almost half that of younger patients. [63] Vural et al's [64] review reports melatonin is effective in older adults, but advises in order to avoid prolonged, supra-physiological blood levels, older adults should use the lowest dose possible of immediate-release melatonin as long-term effects have not been studied.
Abhinav et al [65] reported melatonin is beneficial in older adults for metabolic syndrome components when used in 10-week periods and Haimov et al [66] reported melatonin can be safe and effective for up to two months of treatment.
Quantitative analysis of the five eligible RCTs [44, [46] [47] [48] [49] showed an overall In all five studies for primary insomnia [44] [45] [46] [47] [48] [49] there were large sample sizes, which increased reliability of results (n=40-791). The studies used a thorough prescreening assessment which was deployed to reduce confounding factors and use of medications such as benzodiazepines were stopped beforehand.
Delayed Sleep Phase Syndrome: DSPS is the most common circadian rhythm disorder, causing delayed habitual bedtime and delayed rising time, roughly three to M A N U S C R I P T
13 six hours after conventional sleep-wake times. It is particularly common in adolescents and can be also associated with depression. [67, 68] Meta-analysis of the two eligible trials [52, 53] investigating the role of melatonin in treating DSPS demonstrated an overall significant improvement in sleep onset latency compared with placebo (total mean difference = -22.05 minutes, 95% CI: -32.02, -12.09). The overall estimated score of melatonin treatment was significant (Z=4.34, P<0.0001) (Fig.3) . There was significant heterogeneity between these two studies ( =7.76, P=0.005, I 2 =87%). There was slight asymmetry in the funnel plot, indicating there was potential publicaiton bias present.
The two studies diverged in the way sleep was measured (e.g., PSG versus wrist actigraphy), and by method of melatonin administration (e.g., 5mg daily for four weeks versus 5mg for two weeks double-blind and two weeks open setting, successively or interrupted with two weeks of placebo). Nevertheless, both studies highlighted a decrease in sleep onset latency after melatonin administration.
The third study included for DSPS in this review [51] showed melatonin significantly reduced REM latency and wake time. However, there was no effect on total sleep time or alertness ratings. This indicates a potential role for melatonin in inducing phase-shift in sleep times for patients with DSPS.
One study used adolescents and young adults (aged 16-25) [69, 70] Three studies [54, 55, 58] highlighted the use of melatonin in phase advancement and entrainment of circadian rhythm in patients who are blind. Two of these trials [54, 55] were eligible for meta-analysis. There was no overall significant difference between the effects of melatonin and placebo on sleep onset latency in blind patients (total mean difference = -3.17 minutes, 95% CI: -11.88-5.54). It is speculated that the use of melatonin has no effect when used on nights when the circadian rhythm is congruent with pre-established/routine sleep habits, reinforcing the concept that melatonin does not provoke sleep but facilitates the desire to sleep when awake. [55] The overall estimated score of treatment effect for these patients was not significant (Z=0.71, P=0.48). No significant heterogeneity was found between these compared studies ( =0.00, P=0.99, I 2 =0%). No publication bias was present indicated by the symmetrical funnel plot (Fig.4) .
Only subjective measures were used by Hack et al [54] to assess sleep parameters with a small sample size (n=10). The use of daily diary reporting measures increased the likelihood of bias due to inaccurate reporting and therefore PSG or wrist M A N U S C R I P T
15 actigraphy methods would have been more reliable, more representative of sleep behaviour, and a less erroneous strategy. In comparison, Sack et al [55] used PSG which increased reliability of the findings despite the similarly small sample size (n=7). A reduction in total sleep time after melatonin administration was also shown, due to melatonin inducing additional consolidated sleep in blind patients and shortening their overall sleep time by reducing frequency of daytime napping. Thus, melatonin is an effective treatment to promote the free-running circadian rhythm in these patients, allowing for a more structured 24-hour sleep-wake cycle.
REM-Behaviour Disorder: RBD involves loss of normal voluntary muscle, atonia,
during REM sleep resulting in complex motor behaviour (the body is active instead of being paralysed) when dreaming. RBD is predominantly seen in males and is more common in the elderly. [71] Only one study has addressed the role of melatonin in the treatment of this disorder. There were sufficient pre-screening measures taken before participation in the trial, such as alcohol avoidance and prohibiting exercise, since studies have shown exercise can improve symptoms of RBD. [72] The authors concluded any improvement in sleep parameters was due to melatonin administration alone in this trial.
Discussion
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This review has shown evidence that melatonin has a role in the treatment of some primary sleep disorders, namely primary insomnia, DSPS, non-24 hour sleep-wake disorder in people who are blind, and RBD. Melatonin facilitates achieving better sleep for these patients by reducing the sleep-onset latency [73] or by regulating sleep-wake times to coincide with the natural circulatory cycle, as well as reducing sleep episodes without muscle atonia. [50] The mechanism by which the occurrence of reducing sleep episodes without muscle atonia in RBD is still unknown and requires further study.
The search strategy used in this review was thorough and the inclusion criteria were broad so all relevant publications from a wide variety of sources from 1950 to 2014
were included. There is unpublished research and commercially sponsored work in the area of sleep disorders, but the data were not included in this review due to the fact that unpublished research has not been subject to peer review. Futhermore, commercially sponsored/sensitive work can potentially be biased and/or contain inaccurate data. Kuriyama et al [74] reviewed published and unpublished data from randomised placebo-controlled trials performing an analysis on the efficacy of ramelteon, a selective melatonin receptor agonist used in the treatment of insomnia.
Ramelteon was effective in improving some sleep parameters with insomnia, was not included in the meta-analysis as we focused on exogenous melatonin only. After we had concluded our analysis, Lockley et al [75] published the effectiveness of once-daily tasimelteon, which is a new dual-melatonin receptor agonist in non-24 h sleep/wake disorder in blind people. Tasimelteon was found to be effective in entraining totally blind people, but continued treatment was necessary to maintain the improvements. Again, our focus was on melatonin per se. Brzezinski et al [98] conducted a similar meta-analysis of randomised, placebo-controlled trials of The most relevant databases for this topic were chosen; MEDLINE, EMBASE, and SCOPUS cover a wide range of medical topics from across Europe and internationally and provide studies performed recently. PsycINFO is a comparatively smaller database, but indexes more than journal articles alone; it is also useful for social aspects of medicine. [35] Papers which were included for analysis were reviewed by two authors independently using defined inclusion criteria and then discussed to ensure they were relevant and appropriate. All studies used a variety of sleep measures to assess the effect of melatonin on sleep which provides a broad set of variables, thus impacting on the reliability of results. The symmetrical funnel plots for primary insomnia and blindness demonstrated the negligible publication bias present in this meta-analysis. This use of funnel plots was important as it quantified and evaluated publication bias rather than it being discussed in a superficial and abbreviated manner. Publication bias cannot be excluded through the use of a funnel plot alone, since "…asymmetry should be used when there are at least 10 studies included in the meta-analysis, because when there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry." [77] However, we used this tool to alert us to any problems which needed to be considered in the meta-analysis.
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There were some potential limitations to the review; only published study data were included which may increase susceptibility to publication bias. It was particularly evident in the funnel plot for studies investigating DSPS (Fig.3) , whereby all trials were distributed around the line of no effect; it is unlikely that studies with negative or findings of no effect would be ultimately published. Unfortunately, this is a common theme in scientific and medical publications. Funnel plots give an idea of whether the study results are scattered symmetrically around a central effect of melatonin on primary sleep disorders, however asymmetry may also be due to heterogeneity between the studies. [78] We focused on primary sleep disorders as previous metaanalyses have been conducted on secondary sleep disorders and shift-work diagnosis specifically. [79] Some RCTs included in our meta-analysis had only a small number of participants (Table 1) Numerous studies have also highlighted the use of melatonin in paediatric sleepwake cycle disorders and AD's, [83] however there have been no RCTs or long term studies showing evidence for its therapeutic use in this age group.
Little evidence is available regarding the potential adverse effects of long-term melatonin use as it may take years for the toxicities to develop. [84] Wade et al [48] preformed a trial over six months of daily melatonin use and demonstrated no adverse effects or rebound withdrawal symptoms. Two studies [62, 85] that arise from sleep restriction (e.g., jet lag, shift-work), [4] but the results of their review may be partly attributable to trial limitations similar to those discussed in the current paper.
In conclusion, this review has found evidence from a small number of trials for melatonin in treating primary insomnia, DSPS, and Non 24-hour sleep wake syndrome in people who are blind. Meta-analyses of the data emphasised in particular the improvement of sleep onset latency with melatonin in these patients.
This result has been reproduced in the meta-analysis by Ferracioli-Oda, et al. [9] Based on the current inclusion of melatonin in the management of RBD, it is hoped in future there will be an increase in robust evidence for its widespread use. For such a commonly used medication, there are very few trials which have been performed sufficiently rigorously to examine the long-term efficacy of exogenous melatonin or any long-term side-effects. Clinicians should be alert to these limitations but also aware of the important role exogenously administered melatonin has in the sleep medicine armamentarium.
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Practice Points
1.
Exogenously administered melatonin has been shown to improve sleep onset latency in primary insomnia, DSPS, and to normalise free-running rhythms in people who are blind.
2.
Melatonin may play a role in the treatment of RBD.
3.
There is currently no evidence of efficacy of melatonin for treating arousal disorders in adults.
4.
There is currently no trial evidence for the use of melatonin in secondary insomnia; since this is no longer a diagnosable DSM-V disorder there will probably not be any future studies on secondary insomnia [88] .
Research Agenda
1.
There is an absolute lack of well-structured clinical trials focusing on the utility and efficacy of melatonin in the treatment of RBD, arousal disorders and adult secondary insomnia. 
